new glp 1 agonist novo nordisk Nordisk's weight-loss pill wins FDA approval Diabetes Treatments | Novo Nordisk

Tirzepatide for managing overweight and obesity

With "Retatrutide vs tirzepatide," the difference lies in its additional action on glucagon

The net result is maintained or improved glucose homeostasis, while the energy expenditure and lipolytic benefits of glucagon receptor activation are preserved [3]

GLP-1 signaling activates selective autophagy pathways, including mitophagy for the removal of damaged mitochondria, lipophagy for the degradation of lipid droplets, and aggrephagy for the clearance of protein aggregates

Emerging research suggests that GLP-1 medications may help reduce addictive behaviors, including alcohol cravings and cigarette smoking